Douglas Hunt
General Counsel presso PUMA BIOTECHNOLOGY, INC.
Patrimonio netto: 748 429 $ in data 31/03/2024
Profilo
Douglas Hunt is currently the Senior VP-Law, Regulatory & Medical Affairs at Puma Biotechnology, Inc. He previously worked as the Executive Director-Therapeutic Area at Amgen, Inc. from 2000 to 2008.
From 2008 to 2015, he was the Vice President-Global Regulatory Affairs at Baxter Healthcare Corp.
He then served as the VP-Regulatory Affairs & Quality Assurance at ArmaGen, Inc. from 2015 to 2017.
Mr. Hunt obtained his undergraduate degree from the University of Portsmouth.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
PUMA BIOTECHNOLOGY, INC.
0.29% | 12/02/2024 | 141 213 ( 0.29% ) | 748 429 $ | 31/03/2024 |
Posizioni attive di Douglas Hunt
| Società | Posizione | Inizio |
|---|---|---|
| PUMA BIOTECHNOLOGY, INC. | General Counsel | 01/01/2018 |
Precedenti posizioni note di Douglas Hunt
| Società | Posizione | Fine |
|---|---|---|
ArmaGen, Inc.
 ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | General Counsel | 01/12/2017 |
Baxter Healthcare Corp.
 Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Baxter Healthcare Corp. develops, manufactures, and distributes hospital supplies and medical technologies. It distributes medical treatment options for conditions such as hemophilia, immune disorders, kidney disease, cancer, and trauma. The company was founded on June 21, 1967 and is headquartered in Deerfield, IL. | General Counsel | 01/01/2015 |
| AMGEN INC. | Corporate Officer/Principal | 01/07/2008 |
Formazione di Douglas Hunt
| University of Portsmouth | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| PUMA BIOTECHNOLOGY, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Baxter Healthcare Corp.
Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Baxter Healthcare Corp. develops, manufactures, and distributes hospital supplies and medical technologies. It distributes medical treatment options for conditions such as hemophilia, immune disorders, kidney disease, cancer, and trauma. The company was founded on June 21, 1967 and is headquartered in Deerfield, IL. | Health Technology |
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Health Services |
- Borsa valori
- Insiders
- Douglas Hunt
